In a phase 1 and 2 trial in which mesenchymal stem cells (MSCs), bone marrow mononuclear cells (BMCs), or placebo was used to treat patients with ischaemic cardiomyopathy (n = 65), serious adverse events occurred at a similar rate in all three groups. After 1 year, patients treated with MSCs or BMCs had improved Minnesota Living With Heart Failure scores; this improvement was not seen with placebo. Patients treated with MSCs—but not BMCs or placebo—also had improvements in the 6-minute walk distance, decreased infarct size, and improved regional myocardial function relative to baseline measurements.
References
Heldman, A. W. et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy. The TAC-HFT randomized trial. JAMA 10.1001/jama.2013.282909
Rights and permissions
About this article
Cite this article
Stem cells are safe in ischaemic cardiomyopathy. Nat Rev Cardiol 11, 5 (2014). https://doi.org/10.1038/nrcardio.2013.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2013.191